KymeraTx
Drug Discovery
11open roles
$275kmedian advertised pay
Atruth index, 85 of 100
55 daysmedian time a role stays open
Overview
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
How KymeraTx hires
Truth index
A 85/100
Median time to fill
55 days
Ghost roles
0%
Stale roles
60%
Reposted roles
0%
KymeraTx scores A on the Alion truth index (A is best, E worst), measured over 5 open roles re-checked against its own hiring board: 0% look like ghost listings, 60% have gone stale and 0% are the same role posted again. Its roles close in a median of 55 days. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
Jobs
$85k – $155k per year · In office · Bachelor's Degree · Watertown
HIPAA
Life Sciences
Good Clinical Practice
Apply
$145k – $215k per year · In office · Bachelor's Degree · Watertown
HIPAA
Life Sciences
Good Clinical Practice
Apply
≈ $201k – $351k per year (Estimated) · In office · 10+ years exp · PhD · Watertown
HPLC
GMP
GLP
Apply
$160k – $275k per year · In office · 8+ years exp · Master's Degree · Watertown
Python
SAS
CDISC
Apply
$195k – $330k per year · In office · 10+ years exp · Watertown
Smartsheet
Life Sciences
GMP
GLP
Apply
$160k – $275k per year · In office · 8+ years exp · Bachelor's Degree · Watertown
GCP
Apply
$195k – $330k per year · In office · 10+ years exp · Bachelor's Degree · Watertown
Apply
$195k – $330k per year · In office · 4+ years exp · PhD · Watertown
Microsoft Project
Apply
$235k – $335k per year · In office · Watertown
Prompt Engineering
AI Agents
LLM
OpenAI
Anthropic
DevOps
Azure
Apply
$195k – $275k per year · In office · 12+ years exp · Watertown
SAS
Veeva
MedTech
21 CFR Part 11
Apply
$160k – $240k per year · In office · 8+ years exp · Watertown
GDPR
HIPAA
Life Sciences
Good Clinical Practice
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$275k
Typical range
$155k – $395k
Open positions
17
17
Jobs
Senior
58.8%
Staff
5.9%
Architect
35.3%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 10 | $330k | $155k – $335k |
| Staff | 1 | $215k | $215k |
| Architect | 6 | $275k | $240k – $395k |
Highest paying role
Vice President, Pharmaceutical Development
$395k
Normalized to USD per year
All salaries at KymeraTx
By role, level and city, against the market · 17 jobs with pay
Growth
Hiring Momentum
34/100
Slowing
Open positions
18
0 opened / 2 closed in 30 days
Median time-to-fill
50 days
faster than 27% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Early Careers
44% ▲
Biotech
25% ▼
Leadership
13% ▼
HR
6% ▼
Science & Research
6% ▼
Industrial Engineering
6% ▼
Activity Timeline
Added CDISC to stack
Oct 2026
Added HPLC to stack
Oct 2026
Added GMP to stack
Oct 2026
Added GLP to stack
Oct 2026
Added Good Clinical Practice to stack
Oct 2026
Added Mass Spectrometry to stack
Oct 2026
Added Veeva to stack
Oct 2026
Added 21 CFR Part 11 to stack
Oct 2026
Tech stack
Technologies named in job postings at KymeraTx over the last 12 months, by layer, with the share of postings for each.
Technologies in use
20
Postings analysed
17
Stack modernity
68/100AI adopter
Languages
Python18%
SAS18%
MATLAB6%
Cloud & platforms
GCP18%
Anthropic6%
Azure6%
E2B6%
AI & ML
LLM6%
Sign in to see how your skills match this stack
Sign In
Full KymeraTx tech stack
20 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Atlas VentureVia a fund
Nextech InvestVia a fund
63 portfolio companies: Zymeworks, Vividion Therapeutics (Acquired), Zenith Therapeutics and 60 more
Wellington ManagementVia a fund
Bessemer Venture PartnersVia a fund
502 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the
Read more
Report
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 Kymera Therap
Read more
Report
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing
Read more
Report
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company XQPe_V
Read more
Report
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 XU9c94etPlA7bSlRAH5jCKv
Read more
Report
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director XPJbh5wxnSOqepaFyjY53IPyBK72aKnwFd8X63naB0DdLo=" target="_blank" rel="nofollow"Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a
Read more
Report
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi Xw-V46t3ppW-m0Vg8loC2rrmMOcGpekzm0rXj6c0nkCxRad_A_U=" target="_blank" rel="nofollow"Kymera Therapeutics, Inc. (NASDAQ: KYMR), a cl
Read more
Report
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Penny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer Xajg1JVsQ8mw7IlroZqPlDV5rXp9p0fcux93sx9ESsNxHwDVuNbe38bIzB7MhUVL478LwjtjE0hMbe
Read more
Report
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, i
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Watertown
Watertown
United States
HQ
500 North Beacon Street, 4th Floor, Watertown, MA 02472
20 open roles 17 posted in 90 days 5% engineering 50-200 est. staff $284k Avg Salary
hires for Early Careers, Biotech, Leadership
500 North Beacon Street, 4th Floor, Watertown, MA 02472